Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Fred Hutchinson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Fred Hutchinson Cancer Center